Overcoming the boundaries of gene editing by unlocking the full potential of recombinases.
About us
Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Management Team
Seamless Therapeutics is led by an ambitious management team and an experienced board,
joined by a shared vision to transform the gene editing landscape
Albert Seymour, PhD
President & CEO
Deborah Kinch, PhD
Chief Development Officer
Felix Lansing, PhD
Scientific Co-Founder & CTO
Anne-Kristin Heninger, PhD
Co-Founder & Head of Operations Dresden
Arturo Urrios, PhD, MBA
Head of Business Development
Board Members & Advisors
News & Press Releases
Dresden, Germany and Greater Boston, MA, April 23, 2024
Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform
Careers
We are a dynamic team pioneering a groundbreaking new gene editing approach with a deep understanding of recombinases and their potential in repairing genes that cause serious diseases. We foster creativity, leadership and teamwork, and empower our people to make decisions and contribute positively to our goals. We also offer a supportive environment for colleagues to learn from each other, tackle challenges together and celebrate our achievements.
Interested in working with us?
We are always looking for dedicated and visionary employees with a diverse range of talents and welcome interest from applicants hoping to join us on our mission. Please send a short cover letter and CV with your earliest starting date to